

H K E ... C L ... E H K L ...



上海復星醫藥（集團）股份有限公司
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(P C ...)
(Stock Code: 02196)

2014 FIRST QUARTERLY REPORT

a m ma r a ... 1 .0 (2) a ... 1 .10 ...
r ar I A ... m a ... I rma ...
r ar I A ... a ... (a r⁵ .1 ... a ...)

r r r r r 201 ... a r a ... arma ... (r) ...
* (“Company”, ... b ar ... “Group”). ... a ...
r r r r a ... a ... a ... r r a a
b a ...

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Chen Qiyu
C

a a , ... b ... a
2 r. 201

A ... M. C ... M. F ...
M. G ... M. ... G ... M. ... P ... M. K ... L ...
M. H ... J ... D ... M. L ... M ... A ... D ... M.
C H ...

* F ...

1 IMPORTANT NOTICE

1.1 The Board of Directors of the Company has reviewed the financial statements of the Company for the reporting period, and the financial statements are true and accurate, and the financial statements are prepared in accordance with the applicable accounting standards and the Company's financial reporting policies, and the financial statements are true and accurate, and the financial statements are prepared in accordance with the applicable accounting standards and the Company's financial reporting policies.

1.2 The Board of Directors of the Company has reviewed the financial statements of the Company for the reporting period, and the financial statements are true and accurate, and the financial statements are prepared in accordance with the applicable accounting standards and the Company's financial reporting policies, and the financial statements are true and accurate, and the financial statements are prepared in accordance with the applicable accounting standards and the Company's financial reporting policies.

1. The Board of Directors of the Company has reviewed the financial statements of the Company for the reporting period, and the financial statements are true and accurate, and the financial statements are prepared in accordance with the applicable accounting standards and the Company's financial reporting policies, and the financial statements are true and accurate, and the financial statements are prepared in accordance with the applicable accounting standards and the Company's financial reporting policies.

1. The Board of Directors of the Company has reviewed the financial statements of the Company for the reporting period, and the financial statements are true and accurate, and the financial statements are prepared in accordance with the applicable accounting standards and the Company's financial reporting policies, and the financial statements are true and accurate, and the financial statements are prepared in accordance with the applicable accounting standards and the Company's financial reporting policies.

2 MAJOR FINANCIAL INFORMATION OF THE GROUP AND CHANGES IN SHAREHOLDINGS OF THE COMPANY

2.1 The financial statements of the Company for the reporting period are as follows:

	As at the end of the Reporting Period	As at the end of the previous year	Change recorded at the end of the Reporting Period compared with the end of the previous year (%)
Total Assets (RMB million)	10,622,551.2	2,510,101.1	1.
Total Liabilities (RMB million)	15,211.5	15,211.0	1.
	From the beginning of the year to the end of the Reporting Period (Jan - Mar)	From the beginning of the previous year to the end of the Reporting Period of the previous year (Jan - Mar)	Year-on-year change (%)
Total Assets (RMB million) (N/A)	102,511.1	115,115.5	-0.
	From the beginning of the year to the end of the Reporting Period (Jan - Mar)	From the beginning of the previous year to the end of the Reporting Period of the previous year (Jan - Mar)	Year-on-year change (%)
Total Liabilities (RMB million)	2,512,511.1	2,615,511.2	2.2

A

... a ...

Items	Current Amount (Jan – Mar)	Description
...	0,55,50.	...
...	1,000.00	...
...	11,0,1.21	...
...	-1,5,02.	...
...	0,01.	...
Ima... m... r... (a... r... a...)	5,02,01.	...
...	110,0,0.	...

2.2 ...

... ar

The shareholding status of the Top 10 shareholders					
Name of the shareholder	Capacity	Shareholding (%)	Total number of shares held	Number of restricted shares held	Number of shares pledged or frozen
...	...	1.02	20,1,1	0	...
...	...	1.02	5,5,0	0	...
...	...	1.22	2,0,52	0	...
...	...	0.	1,21,0	0	...
...	...	0.0	1,000,000	0	...
...	...	0.	1,0,22	0	...
...	...	0.	1,02,0	0	...
...	...	0.5	12,5,1	0	...
...	...	0.51	11,0,5	0	...
...	...	0.5	10,12,0	0	...

The shareholding status of the Top 10 unrestricted shareholders of tradable shares

Name of the shareholder (in full)	Number of unrestricted tradable shares held at the end of the reporting period	Type and number of shares
A... ()...	20,1,1	r ar ar
I.I. (N,)	5, 5, 0	r ar ar
10 r	2, 52	r ar ar
— a r I m	1, 2 1, 1	r ar ar
I r a a m m r e a a — J r a a e b - e e r I m	1,000,000	r ar ar
11 r	1, , 22	r ar ar
b e e r I m	1, 02, 0	r ar ar
I r a a m m r e a a — a e e e r I m	12, 5, 1	r ar ar
a m m e a — a r a r e r m m e e r I m	11, 5, 1	r ar ar
I r a e m a — r b — r a — 01 — 002	10,1 2, 0	r ar ar
r a r a e e r a e e e a b ar r	m a r b e a — a r e a — a e e r I m a a m m e a — a r a r e r m m e e r I m a a a a m m e e r a b e a — a b e e r I m a e e r I m a r e a m a a r a r a a e e r a b e a r ar r a b ar .	

N₁: I.I., r a r m a m m e e r a r b a m e e

3 SIGNIFICANT EVENTS

1. ^A ^A

_____ a _____

Balance Sheet				
Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year	Ratio of change	Reasons
_____	2,0 _____,121.20	1, _____, 00, 2 ⁵	_____ %	_____
_____	2, 2 ⁵ , 1. 2	12, 1, 1, 1. 2	11%	_____
Income Statement				
Items	Current Amount	Amount of the last period	Ratio of change	Reasons
	(Jan – Mar 2014)	(Jan – Mar 2013)		
_____	1,555,0 _____	1,1 2 ⁵ , 0 ⁵	_____ %	_____
^A _____	1, 2 ⁵ , 2 _____ 2	2 _____, 0 _____, 110.1	5%	_____ & _____
_____	1 ⁵ , 5, 0 1.	2, 5 1, 2 _____	-5%	_____
_____	_____ 01, 1, _____ 2	2 ⁵ , 200, 01 _____ 1	_____ %	_____
_____	_____ _____, 0 _____ 0 ⁵	1 _____, 0 _____, _____	5%	_____
_____	2, 11, _____	_____ 0, 0 _____, _____ 0	5%	_____
_____	_____ _____, 10 _____ 2 ⁵	2 ⁵ , _____, _____	-52%	_____ ^A _____ ^A

() 2 br ar 201 , m a • r m (r a r ar)
ar , a • a ar a a a ar ma • a
I r a m m * (上

4 APPENDICES

Consolidated Balance Sheet

31 M . 2014

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Current Assets:		
cash and cash equivalents	1,020,050.00	1,000,000.00
receivables		
prepaid expenses		
inventory	1,000,000.00	1,000,000.00
other current assets	1,000,000.00	1,000,000.00
total current assets	3,020,050.00	3,000,000.00
long-term investments		
fixed assets		
land and buildings		
equipment		
intangible assets		
total non-current assets		
total assets		
liabilities		
current liabilities		
long-term liabilities		
total liabilities		
equity		
total equity		
total liabilities and equity		

Balance Sheet of the Company

31 M . . . 2014

r . ar b . Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Current Assets:		
a a ba ba a *	1,0P, 0 . 0	2,11, 5 . 1
a a a r r a r		
r * ab		
ra r * ab		
r a m		
I r r * ab	121, 0 . 5	2,55, 55 . 0
r * ab	1, 5 ,22 .	1, 5 ,22 .
r r * ab	1, 0,02 ,55 .1	1, , ,21 .0
I r r	51, , ,	51, , ,
r r a ar		
r r a	,000,000.00	2,5,000,000.00
a * r a	, , 0, 2 . 1	,0 2,0P,22 . 5
Non-current assets:		
A a ab - r - a a a a		
- ma r m		
r m r * ab		
r - rm m	5, 2, 5 , , 5 . 0	5, 0, 55 . 2.
I m r r		
a	1, , 2 .1	20,15,0 .
r * r r		
r *		
a a		
r * b r a a		
a a a		
I a b a	2, 0 , 11 .	,05, 0 . 5 2
m r		
r m r r		
r r m a a		
r r r a	, 51, , 5 . P	,0 2, , 2 2 . 0
a - r a	, , 5 , 0 .	, , , 1 , 5 . 5
a a	1, 1 , 2 , 0 .	12,55 , 2,1 . 0

Balance Sheet of the Company (Continued)

31 M . . . 2014

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Current liabilities:		
r - rm . a	10,000,000.00	0,000,000.00
a . e a . ab r ra . r		
. . . a ab		
ra . . a ab		
. . e . . . a a . e		
ar . . a ab	5 , 5 0 , . . .	0 , 2 , 11 . . .
a . . a ab	1 , 1 , 0 5 . 02	22,22 , . . .
I . r . . a ab	10 , 2 2 , 0 . .	1 , , 5 , 5 1 . . .
. . . a ab		
r . a ab	, , 1 , 5 . . .	, , , 12 , 2 5 .
. . e rr . . ab ar	0,000,000.00	0,000,000.00
r . e rr . . ab		
. . a . e rr . . ab	1,0 , 5 , 5 . 2	2 , 02 , 0 1 . 0 5
Non-current liabilities:		
r - rm . a	2 5 , 000,000.00	12 5 , 000,000.00
. . . a ab	, 0 5 , 2 , . 1 .	, 0 , , 1,2 0 . .
r - rm . a ab		
. . e . e a ab		
A e rr . . ab		
rr . . e m a . . ab		
r . . e rr . . ab	1 , 5 , 000.00	2,0 5 0,000.00
a . . . e rr . . ab	, , 02, 02 , . 1 .	, , 200 , 1,2 0 . .
a . ab	5 , , , 1 5 5 . 5	, , 2 , , 2 1 5 .
Equity attributable to the owners (or equity attributable to shareholders):		
a . a . e a a (r ar , e a a)	2,2 , , , , . 00	2,2 0 , 2 , . 00
a a r r	, , , 20 , 2 . .	, , , 1,2 . 1
r a r ar		
. . e . e r r		
r . . r r	5 , , , 0,1 5 .	5 , , , 0,1 5 .
ra r r r		
a . r . ra . r r	1,0 5 , 22, 11 .	1,0 5 , 1,0 1 . 2
. . a . . . a r b ab r (r . . . a r b ab . . . ar . . r)	, , 5 , 1 , , 1 . 0	, , 1 , , , . 0
. . a . ab . . . a . . . a r b ab r (r . . . a r b ab . . . ar . . r)	1 , 1 , 2 , 0 . . .	12,5 5 , 2,1 . . 0

r a . . . r . . a a . e a . . . e r
r . e . r A
. . m a J a
. . ar m a . J a

Income Statement of the Company

July 1 - Dec 31, 2014

Parent: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Items	Current Amount	Amount of the Last Period
I. Operating Profit		
Operating Revenue		
Operating Expenses		
Operating Profit	2,101,150	20,200,020
Operating Expenses	-1,200,000	-20,000,000
Operating Profit		
Operating Expenses		
Operating Profit	2,102,200	20,000,000
Operating Expenses	2,000,000	5,500,000
Operating Profit	-1,020,000	25,500,000
Operating Expenses	5,000.00	0.00
Operating Profit	2,000,000	5,110,000
Operating Expenses		
Operating Profit	-1,200,000	25,000,000
Operating Expenses		
Operating Profit	-1,200,000	25,000,000
Operating Expenses		
Operating Profit	-0.00	0.12
Operating Expenses	-0.00	0.12
Operating Profit		5,000.00
Operating Expenses	-1,200,000	25,000,000

Parent: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Consolidated Statements of Cash Flows (Continued)

July 1 - June 30, 2014

Items	Current Amount	Amount of the Last Period
III. Cash flow generated from financing activities:		
Increase in short-term debt	5,100.00	
Increase in long-term debt	5,100.00	
Decrease in short-term debt	(152,515.5)	(1,050,000.00)
Decrease in long-term debt		
Increase in accounts payable	21,555	
Decrease in accounts payable	(220,20)	(1,050,000.00)
Increase in other liabilities	125,252	(1,050,000.00)
Decrease in other liabilities	(20,222)	(1,050,000.00)
Increase in other assets	(1,000,000.00)	(51,250)
Decrease in other assets	(1,000,000.00)	(2,000.00)
Increase in other assets	(5,010)	(52,000)
Decrease in other assets	(1,000,000.00)	(1,000,000.00)
IV. Effects of exchange rate fluctuations on cash and cash equivalents	(1,000,000.00)	(1,000,000.00)
V. Net increase of cash and cash equivalents	(1,000,201.00)	(55,212.00)
Increase in cash and cash equivalents	(2,120,000.00)	(1,150,000.00)
VI. Closing balance of cash and cash equivalents	(2,520,510.00)	(55,212.00)

Director
A
Manager
Director

Statements of Cash Flows of the Company (Continued)

Juli 2014 – März 2015

Items	Current Amount	Amount of the Last Period
III. Cash flow generated from financing activities:		
a r e r m e a a e r b		
a r e r m b r	5 0,000,000.00	
a r e r m b		
r e a r e r a r a e r a e	1, , , . 1	5, 5, . 1. 0
b a e a r m a e r a e	2, 2, , , . 1	5, 5, . 1. 0
a a r b m		
a a r r b , r r r a m	10, 1, , 55.55	10, 5 00,000.00
r e a a r a r a e r a e	1, 55, 2, , .	02, , 0 . 2
b a e a r m a e r a e	1, 5, , 2, . 1.	0, 1, , 0 . 2
e a r a r m a e r a e	5, 1, 5 1.	-2, 211, 0 . 22
IV. Effects of exchange rate fluctuations on cash and cash equivalents	, 12, , . 1	5, 5, 2, . 1
V. Net increase of cash and cash equivalents	-5, 11, 5 2.11	-5, 2, 1, , 2.
b a e e a a e a	5 1, 2 2, 5 . 1	2, 0 0, 1, 0 .
VI. Closing balance of cash and cash equivalents	5 0, 1 5, 0 . 0	1, , , 1, 5 0.

r a r a
a e a e r
r e r e
A
m a
J a
a r m a J a

* F - s 300 0 3 0 1 0 1 1 3 -